Vera Therapeutics, Inc. Stock-Based Compensation
Vera Therapeutics, Inc. (VERA) reported Stock-Based Compensation of $29.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- Vera Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $15.86M, a 67.47% increase year-over-year.
- Vera Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $13.21M, a 70.56% increase year-over-year.
- Vera Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $10.96M, a 76.37% increase year-over-year.
- Vera Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $9.74M, a 74.39% increase year-over-year.
- Vera Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $37.93M, a 82.32% increase from fiscal 2024.
- Vera Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $20.80M, a 81.00% increase from fiscal 2023.
- Vera Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $11.49M, a 29.32% increase from fiscal 2022.
- Vera Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $8.89M, a 195.05% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $29.07M 10-Q · filed 2026-08-10 | $40.04M derived: sum of 3 quarters · filed 2026-08-10 | $49.78M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $13.21M 10-Q · filed 2026-05-07 | $24.17M derived: sum of 2 quarters · filed 2026-05-07 | $33.92M derived: sum of 3 quarters · filed 2026-05-07 | $43.39M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $10.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $20.71M derived: sum of 2 quarters · filed 2026-02-26 | $30.18M derived: sum of 3 quarters · filed 2026-08-10 | $37.93M 10-K · filed 2026-02-26 |
| 2025-09-30 | $9.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $19.22M derived: sum of 2 quarters · filed 2026-08-10 | $26.96M 10-Q · filed 2025-11-05 | $33.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $9.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $17.22M 10-Q · filed 2026-08-10 | $23.43M derived: sum of 3 quarters · filed 2026-08-10 | $29.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $7.74M 10-Q · filed 2026-05-07 | $13.96M derived: sum of 2 quarters · filed 2026-05-07 | $19.55M derived: sum of 3 quarters · filed 2026-05-07 | $24.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.80M derived: sum of 2 quarters · filed 2026-02-26 | $16.68M derived: sum of 3 quarters · filed 2026-02-26 | $20.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $10.46M derived: sum of 2 quarters · filed 2025-11-05 | $14.59M 10-Q · filed 2025-11-05 | $17.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $9.00M 10-Q · filed 2025-08-05 | $12.22M derived: sum of 3 quarters · filed 2026-02-26 | $15.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.12M 10-Q · filed 2025-05-07 | $7.34M derived: sum of 2 quarters · filed 2026-02-26 | $10.27M derived: sum of 3 quarters · filed 2026-02-26 | $12.95M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.14M derived: sum of 2 quarters · filed 2026-02-26 | $8.83M derived: sum of 3 quarters · filed 2026-02-26 | $11.49M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.61M derived: sum of 2 quarters · filed 2024-11-07 | $8.27M 10-Q · filed 2024-11-07 | $11.02M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.35M 10-Q · filed 2024-08-08 | $8.10M derived: sum of 3 quarters · filed 2024-08-08 | $10.55M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.67M 10-Q · filed 2024-05-10 | $5.42M derived: sum of 2 quarters · filed 2024-05-10 | $7.87M derived: sum of 3 quarters · filed 2024-05-10 | $9.89M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $5.20M derived: sum of 2 quarters · filed 2024-03-27 | $7.22M derived: sum of 3 quarters · filed 2024-03-27 | $8.89M 10-K · filed 2024-03-27 |
| 2022-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.48M derived: sum of 2 quarters · filed 2023-11-09 | $6.14M 10-Q · filed 2023-11-09 | $7.10M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.69M 10-Q · filed 2023-08-10 | $4.65M derived: sum of 3 quarters · filed 2023-08-10 | $5.58M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.66M 10-Q · filed 2023-05-11 | $2.62M derived: sum of 2 quarters · filed 2023-05-11 | $3.56M derived: sum of 3 quarters · filed 2023-05-11 | $4.27M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $962.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $1.90M derived: sum of 2 quarters · filed 2023-03-28 | $2.61M derived: sum of 3 quarters · filed 2023-03-28 | $3.01M 10-K · filed 2023-03-28 |
| 2021-09-30 | $933.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.65M derived: sum of 2 quarters · filed 2022-11-09 | $2.05M 10-Q · filed 2022-11-09 | $2.19M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $713.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.12M 10-Q · filed 2022-08-10 | $1.26M derived: sum of 3 quarters · filed 2022-08-10 | $1.38M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $404.00K 10-Q · filed 2022-05-16 | $547.00K derived: sum of 2 quarters · filed 2022-05-16 | $663.00K derived: sum of 3 quarters · filed 2022-05-16 | $674.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $259.00K derived: sum of 2 quarters · filed 2022-03-28 | $270.00K derived: sum of 3 quarters · filed 2022-03-28 | $331.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $127.00K derived: sum of 2 quarters · filed 2021-11-10 | $188.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $72.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $61.00K 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |